France sets up agency for medical bioethics
By Agence France-Presse,
Agence France-Presse
| 05. 10. 2005
PARIS (AFP) - France inaugurated a specialised agency for approving research on embryonic stem cells and vetting organ donations and other bioethics issues.
The creation of the Biomedicine Agency follows up on a new law, approved by parliament last August and due to take effect this month.
Under it, French health scientists will be permitted to draw on the country's stock of tens of thousands of surplus embryos in order to create lines of stem cells.
These embryos were created years ago through in-vitro fertilisation (IVF) to help infertile couples, but are no longer wanted and remain in freezers in fertility clinics.
Stem cells are immature cells that are like blank slates. In this early state, they have yet to differentiate into the specific cells that make up the body's tissues.
The goal among scientists is to harvest these cells and coax them into growing into fresh, replacement tissue which can then be transplanted into the body to reverse brain, nerve, muscle and organ damage.
The most versatile stem cells come from embryos that are a few days old. These...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...